Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma. Hematology. 2019 Dec;24(1):440-445 Authors: Wang X, Wu J, Zhang M Abstract Anaplastic lymphoma kinase negative anaplastic large cell lymphoma (ALK- ALCL) is a definite entity in the WHO 2016 Classification that represents 2-3% of non-Hodgkin lymphoma (NHL) and 12% of T-cell NHL cases. ALK- ALCL lacks ALK protein expression, but expresses CD30 and has morphologic features similar to ALK positive anaplastic large cell lymphoma (ALK+ ALCL). Some studies indicate that ALK- ALCL and ALK+ ALCL possess different molecular and genetic characteristics. Besides, ALK- ALCL is worse than ALK+ ALCL in terms of treatment outcome, prognosis, and long-term survival. This review is aimed at summarizing information about ALK- ALCL, especially with respect to the treatment and prognosis. PMID: 31072226 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research